http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20120094557-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caec7099b724bb45d2518787825aab94 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2011-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62e936d08608eb50b0bc60dbc0e6c3c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adceb15274168cf427ae6a6ccf652107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56a3a3f3f85b261bed08c2f952df467e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8113556e7d23547e96f4c66adc53ec78 |
| publicationDate | 2012-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20120094557-A |
| titleOfInvention | Arrhythmia drug formulation with PH-independent dissolution pattern |
| abstract | The present invention relates to a coprecipitation form containing dronedarone or a pharmaceutically acceptable salt, which has a pH-independent dissolution pattern for dronedarone-containing preparations, which are therapeutic agents for arrhythmia. It relates to a solid dispersion or a solid liquid and a preparation containing the same. The dronedarone-containing solid dispersion or solid liquid according to the present invention can increase the dissolution rate in the fast-state at low pH by maximizing the dissolution rate of the main component in acid and is very very even when changing from acid to alkaline environment. Maintaining dronedarone in small particles or dissolved state can increase the low bioavailability of dronedarone or its salts, or reduce the food effect that varies bioavailability depending on the pre- and post-dose administration methods. Therefore, the dronedarone preparation containing the solid dispersion or the solid liquid of dronedarone according to the present invention enables the patient to take the drug comfortably regardless of the preprandial and postprandial regimen, and can reduce the administration size. It can increase medication compliance. |
| priorityDate | 2011-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 121.